GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets closed

Gilead Sciences Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
72.42-0.42 (-0.58%)
At close: 4:00 PM EST
People also watch:
CELGBIIBAMGNREGNBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close72.84
Open73.04
Bid72.35 x 100
Ask72.45 x 400
Day's Range72.16 - 73.59
52 Week Range71.39 - 104.79
Volume8,391,314
Avg. Volume9,617,612
Market Cap95.41B
Beta0.93
PE Ratio (TTM)6.70
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.88 (2.55%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forget Pfizer: Here Are 3 Better Dividend Stocks
    Motley Fool10 hours ago

    Forget Pfizer: Here Are 3 Better Dividend Stocks

    Love dividends? Check out these three.

  • Barrons.com15 hours ago

    Gilead Sciences: Forget About Hepatitis C…Everyone Else Is

    After hosting a dinner with Gilead Sciences (GILD), Piper Jaffray's Joshua Schimmer and team contend that investor attention is finally beginning to turn away from hepatitis C. They explain: We hosted ...

  • Reuters16 hours ago

    EU health regulator warns some hep C drugs could reactivate hep B

    The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments. The Pharmacovigilance Risk Assessment Committee (PRAC), part of the EMA, said it suspected the reactivation of the hepatitis B virus was due to the rapid reduction of the hepatitis C virus, which is known to suppress the hepatitis B virus.